Documents

59142

Supelco

SUPELCOSIL LC-ABZ HPLC Column

5 μm particle size, L × I.D. 25 cm × 4.6 mm

eCl@ss:
32110501

Quality Level

Agency/Method

suitable for USP L60

feature

endcapped

manufacturer/tradename

SUPELCOSIL

extent of labeling

12.0% carbon loading

parameter

≤70 °C temp. limit
400 bar pressure (5801 psi)

application(s)

HPLC: suitable

L × I.D.

25 cm × 4.6 mm

surface coverage

surface coverage 3.4 μmol/m2

matrix

silica gel, spherical particle platform

matrix active group

amide, alkyl phase

particle size

5 μm

pore size

120 Å

surface area

170 m2/g

pH range

2 - 7.5

Featured Industry

Food and Beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

SUPELCOSIL LC-ABZ phase has a unique deactivation technology which provides excellent reversed-phase performance for basic compounds, as well as those that are acidic, polar neutral, and non-polar. Silanol suppressing practices such as using competing amines, operating at high ionic strength, and adjusting mobile phases to pH extremes are typically not required to obtain good peak shape on the LC-ABZ phase.

Features and Benefits

• For acids, bases, zwitterions
• Increased polar retention relative to standard reversed-phases
• Unique selectivity
• Silanol deactivation
• Peak shape, efficiency, and retention are comparable to C8 phases for non-polar analytes

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

SUPELCOSIL is a trademark of Sigma-Aldrich Co. LLC
Certificate of Analysis
Certificate of Origin
D Korakas et al.
Journal of pharmaceutical and biomedical analysis, 12(9), 1141-1145 (1994-09-01)
A series of biologically active peptides and their conjugates with lipidic amino acids were investigated by systematic change of the mobile phase composition using traditional octadecylsilica stationary phase and the newly developed Supelcosil LC-ABZ column. The mobile phases contained various...
Murali Pendela et al.
Journal of separation science, 32(20), 3418-3424 (2009-09-19)
Streptomycin (SM) is composed of streptidine, streptose and N-methyl glucosamine sugar moieties. For the determination of SM and its related substances, an ion-pair LC-UV detection method using a Supelcosil LC-ABZ column was developed previously. While analyzing commercial samples, several unknown...
Q C Li et al.
Journal of chromatographic science, 38(6), 246-254 (2000-07-13)
Nevirapine (Viramune), a dipyridiodiazepinone, is a potent and highly specific nonnucleoside inhibitor of HIV-1 reverse transcriptase. This paper describes the validation of a specific, sensitive, and stability-indicating high-performance liquid chromatography method for the assay and determination of related organic impurities...
J A López et al.
Journal of chromatography. A, 870(1-2), 105-114 (2000-03-18)
A high-performance liquid chromatographic method with electrochemical detection has been developed for the determination of six 1,4-dihydropyridines: nifedipine, nimodipine, nisoldipine, nicardipine, felodipine and lacidipine. The chromatographic separation was performed using a Supelcosil LC-ABZ+Plus C18 column. A mobile phase of methanol-water...
Ana B Baranda et al.
Journal of chromatography. A, 1031(1-2), 275-280 (2004-04-03)
A high-performance liquid chromatographic method with electrochemical detection was developed for the simultaneous determination of five 1,4-dihydropyridines: amlodipine, nitrendipine, felodipine, lacidipine and lercanidipine. These drugs are widely used in the treatment of hypertension, angina pectoris and the therapy of cerebrovascular...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.